ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy. Our technology addresses the need to differentiate cancerous from non-cancerous tissues impacting the safety of the treatment which is to date a major limitation in reaching effectiveness. The company’s technology is based on the work of Prof. Gideon Gross (MIGAL – Galilee Research Institute), who is one of the pioneers of the world’s first CAR-T construct.